|
1
|
Wilhelm S, Carter C, Lynch M, Lowinger T,
Dumas J, Smith RA, Schwartz B, Simantov R and Kelley S: Discovery
and development of sorafenib: A multikinase inhibitor for treating
cancer. Nat Rev Drug Discov. 5:835–844. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu L, Cao Y, Chen C, Zhang X, McNabola A,
Wilkie D, Wilhelm S, Lynch M and Carter C.: Sorafenib blocks the
RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor
cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer
Res. 66:11851–11858. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: SHARP Investigators Study Grou: Sorafenib in advanced
hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of
sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: A phase III randomised, double-blind,
placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kane RC, Farrell AT, Saber H, Tang S,
Williams G, Jee JM, Liang C, Booth B, Chidambaram N, Morse D, et
al: Sorafenib for the treatment of advanced renal cell carcinoma.
Clin Cancer Res. 12:7271–7278. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Keating GM and Santoro A: Sorafenib: A
review of its use in advanced hepatocellular carcinoma. Drugs.
69:223–240. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gauthier A and Ho M: Role of sorafenib in
the treatment of advanced hepatocellular carcinoma: An update.
Hepatol Res. 43:147–154. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Levine B and Klionsky DJ: Development by
self-digestion: Molecular mechanisms and biological functions of
autophagy. Dev Cell. 6:463–477. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Czaja MJ, Ding WX, Donohue TM Jr, Friedman
SL, Kim JS, Komatsu M, Lemasters JJ, Lemoine A, Lin JD, Ou JH, et
al: Functions of autophagy in normal and diseased liver. Autophagy.
9:1131–1158. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kondo Y, Kanzawa T, Sawaya R and Kondo S:
The role of autophagy in cancer development and response to
therapy. Nat Rev Cancer. 5:726–734. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ding ZB, Hui B, Shi YH, Zhou J, Peng YF,
Gu CY, Yang H, Shi GM, Ke AW, Wang XY, et al: Autophagy activation
in hepatocellular carcinoma contributes to the tolerance of
oxaliplatin via reactive oxygen species modulation. Clin Cancer
Res. 17:6229–6238. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Luo T, Fu J, Xu A, Su B, Ren Y, Li N, Zhu
J, Zhao X, Dai R, Cao J, et al: PSMD10/gankyrin induces autophagy
to promote tumor progression through cytoplasmic interaction with
ATG7 and nuclear transactivation of ATG7 expression. Autophagy.
12:1355–1371. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shimizu S, Takehara T, Hikita H, Kodama T,
Tsunematsu H, Miyagi T, Hosui A, Ishida H, Tatsumi T, Kanto T, et
al: Inhibition of autophagy potentiates the antitumor effect of the
multikinase inhibitor sorafenib in hepatocellular carcinoma. Int J
Cancer. 131:548–557. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shi YH, Ding ZB, Zhou J, Hui B, Shi GM, Ke
AW, Wang XY, Dai Z, Peng YF, Gu CY, et al: Targeting autophagy
enhances sorafenib lethality for hepatocellular carcinoma via ER
stress-related apoptosis. Autophagy. 7:1159–1172. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Park MA, Zhang G, Martin AP, Hamed H,
Mitchell C, Hylemon PB, Graf M, Rahmani M, Ryan K, Liu X, et al:
Vorinostat and sorafenib increase ER stress, autophagy and
apoptosis via ceramide-dependent CD95 and PERK activation. Cancer
Biol Ther. 7:1648–1662. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tai WT, Shiau CW, Chen HL, Liu CY, Lin CS,
Cheng AL, Chen PJ and Chen KF: Mcl-1-dependent activation of Beclin
1 mediates autophagic cell death induced by sorafenib and SC-59 in
hepatocellular carcinoma cells. Cell Death Dis. 4:e4852013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lin CI, Whang EE, Lorch JH and Ruan DT:
Autophagic activation potentiates the antiproliferative effects of
tyrosine kinase inhibitors in medullary thyroid cancer. Surgery.
152:1142–1149. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bareford MD, Hamed HA, Tang Y,
Cruickshanks N, Burow ME, Fisher PB, Moran RG, Nephew KP, Grant S
and Dent P: Sorafenib enhances pemetrexed cytotoxicity through an
autophagy-dependent mechanism in cancer cells. Autophagy.
7:1261–1262. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sajithlal GB, Hamed HA, Cruickshanks N,
Booth L, Tavallai S, Syed J, Grant S, Poklepovic A and Dent P:
Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma
viral proto-oncogene inhibition interact to kill tumor cells. Mol
Pharmacol. 84:562–571. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Grignani G, Palmerini E, Ferraresi V,
DAmbrosio L, Bertulli R, Asaftei SD, Tamburini A, Pignochino Y,
Sangiolo D, Marchesi E, et al: Italian Sarcoma Group: Sorafenib and
everolimus for patients with unresectable high-grade osteosarcoma
progressing after standard treatment: A non-randomised phase 2
clinical trial. Lancet Oncol. 16:98–107. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Flaherty KT, Lee SJ, Zhao F, Schuchter LM,
Flaherty L, Kefford R, Atkins MB, Leming P and Kirkwood JM: Phase
III trial of carboplatin and paclitaxel with or without sorafenib
in metastatic melanoma. J Clin Oncol. 31:373–379. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Paz-Ares LG, Biesma B, Heigener D, von
Pawel J, Eisen T, Bennouna J, Zhang L, Liao M, Sun Y, Gans S, et al
NSCLC [non-small-cell lung cancer] Research Experience Utilizing
Sorafenib (NExUS) Investigators Study Group: Phase III, randomized,
double-blind, placebo-controlled trial of gemcitabine/cisplatin
alone or with sorafenib for the first-line treatment of advanced,
nonsquamous non-small-cell lung cancer. J Clin Oncol. 30:3084–3092.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Banerjee S, Wang Z, Kong D and Sarkar FH:
3,3′-Diindolylmethane enhances chemosensitivity of multiple
chemotherapeutic agents in pancreatic cancer. Cancer Res.
69:5592–5600. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Turrini E, Ferruzzi L and Fimognari C:
Natural compounds to overcome cancer chemoresistance: Toxicological
and clinical issues. Expert Opin Drug Metab Toxicol. 10:1677–1690.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fas SC, Baumann S, Zhu JY, Giasi M,
Treiber MK, Mahlknecht U, Krammer PH and Li-Weber M: Wogonin
sensitizes resistant malignant cells to TNF- and TRAIL-induced
apoptosis. Blood. 108:3700–3706. 2007. View Article : Google Scholar
|
|
26
|
Zhao Y, Li H, Gao Z, Gong Y and Xu H:
Effects of flavonoids extracted from Scutellaria baicalensis Georgi
on hemin-nitrite-H2O2 induced liver injury.
Eur J Pharmacol. 536:192–199. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ma SC, Du J, But PP, Deng XL, Zhang YW,
Ooi VE, Xu HX, Lee SH and Lee SF: Antiviral Chinese medicinal herbs
against respiratory syncytial virus. J Ethnopharmacol. 79:205–211.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kimura Y, Okuda H and Ogita Z: Effects of
flavonoids isolated from Scutellariae radix on fibrinolytic system
induced by trypsin in human umbilical vein endothelial cells. J Nat
Prod. 60:598–601. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chi YS, Lim H, Park H and Kim HP: Effects
of wogonin, a plant flavone from Scutellaria radix, on skin
inflammation: In vivo regulation of inflammation-associated gene
expression. Biochem Pharmacol. 66:1271–1278. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Polier G, Ding J, Konkimalla BV, Eick D,
Ribeiro N, Köhler R, Giaisi M, Efferth T, Desaubry L, Krammer PH
and Li-Weber M: Wogonin and related natural flavones are inhibitors
of CDK9 that induce apoptosis in cancer cells by transcriptional
suppression of Mcl-1. Cell Death Dis. 2:e1822011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chung H, Jung YM, Shin DH, Lee JY, Oh MY,
Kim HJ, Jang KS, Jeon SJ, Son KH and Kong G: Anticancer effects of
wogonin in both estrogen receptor-positive and -negative human
breast cancer cell lines in vitro and in nude mice xenografts. Int
J Cancer. 122:816–822. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
He F, Wang Q, Zheng XL, Yan JQ, Yang L,
Sun H, Hu LN, Lin Y and Wang X: Wogonin potentiates
cisplatin-induced cancer cell apoptosis through accumulation of
intracellular reactive oxygen species. Oncol Rep. 28:601–605.
2012.PubMed/NCBI
|
|
33
|
Lee E, Enomoto R, Koshiba C and Hirano H:
Inhibition of P-glycoprotein by wogonin is involved with the
potentiation of etoposide-induced apoptosis in cancer cells. Ann N
Y Acad Sci. 1171:132–136. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang X, Ju W, Renouard J, Aden J, Belinsky
SA and Lin Y: 17-Allylamino-17-demethoxygeldanamycin
synergistically potentiates tumor necrosis factor-induced lung
cancer cell death by blocking the nuclear factor-kappaB pathway.
Cancer Res. 66:1089–1095. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhao L, Wientjes MG and Au JL: Evaluation
of combination chemotherapy: Integration of nonlinear regression,
curve shift, isobologram, and combination index analyses. Clin
Cancer Res. 10:7994–8004. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lee DH, Kim C, Zhang L and Lee YJ: Role of
p53, PUMA, and Bax in wogonin-induced apoptosis in human cancer
cells. Biochem Pharmacol. 75:2020–2033. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Baumann S, Fas SC, Giaisi M, Müller WW,
Merling A, Gülow K, Edler L, Krammer PH and Li-Weber M: Wogonin
preferentially kills malignant lymphocytes and suppresses T-cell
tumor growth by inducing PLCgamma1- and Ca2+-dependent
apoptosis. Blood. 111:2354–2363. 2008. View Article : Google Scholar : PubMed/NCBI
|
